




Take the next evolutionary step in the daily nAMD challenge: the RetInSight Fluid Monitor



The RetInSight Fluid Monitor is a reliable and accurate AI-based “fluid activity meter” for the monitoring of disease progression and therapeutic response in patients with nAMD¹.

It supports the optimisation and personalisation of therapy, with the aim of improving patient outcomes and increasing clinical efficiency. A concise result report is produced at the click of a mouse while the patient is on site.

What does the RetInSight Fluid Monitor do?

- > **Identifies, localises and quantifies retinal fluid in routine OCT images** in a fast, objective and precise manner.
- > **Assigns a label to each OCT pixel** denoting its fluid type as intraretinal fluid (IRF), subretinal fluid (SRF) or pigment epithelial detachment-related fluid (PED) when present, as well as its location within the central 1-mm and 6-mm macular area.
- > **Provides precise volumes in nanoliters**, supporting treatment decisions on the date of the visit as well as monitoring of changes over time.

¹Schmidt-Erfurth U. et al. “AI-based monitoring of retinal fluid in disease activity and under therapy.” Progress in retinal and eye research vol. 86 (2022): 100972.

Which potential advantages does the RetInSight Fluid Monitor bring?



For eye care specialists:

A solid basis for confident treatment decisions and long-term monitoring



For patients:

Increased trust and compliance with the therapy



For hospitals and clinics:

An opportunity to demonstrate quality of care



For hospital and clinic administrators:

Gaining better insight into the budget spent on nAMD and improving resource allocation





Get the whole picture at a glance

In just a few minutes, the RetInSight Fluid Monitor provides a concise PDF report while the patient is on site.



Compatible with the leading OCT systems

The RetInSight Fluid Monitor is intended to be compatible with all leading OCT systems, starting with the Heidelberg Engineering SPECTRALIS® OCT platform.

Reliable accuracy

A detailed analysis demonstrated high accuracy compared to human expert readers and published benchmarks, as well as high reliability at (narrow) 95% CI (submitted for publication).

Fulfils all MDR requirements

The RetInSight Fluid Monitor fulfills all MDR 2017/745 requirements for class IIa medical devices as a Clinical Decision Support System (CDSS) for the monitoring of patients with nAMD.



If you want to **use the RetInSight Fluid Monitor** in your clinical practice, please visit www.retinsight.com or let us know via contact@retinsight.com

About RetInSight:

RetInSight is the first company to introduce an MDR CE-certified AI-solution for use in clinical routine by eye care specialists. It offers transformational OCT image analysis with a clear vision: Living longer shall not mean seeing less.

To accomplish this, RetInSight develops AI solutions for therapeutic monitoring and diagnostic screening according to the highest standards. RetInSight further owns an extensive library of validated algorithms for use in (bio)pharmaceutical clinical and scientific studies. Upon certification, these algorithms are made available for clinical practice. In this way, RetInSight helps bridge the gap between superior outcomes observed in clinical trials and inferior benefits obtained at high cost in the real world, for the leading retinal diseases of our time.

